Literature DB >> 34172096

Proceedings of the Canadian Thyroid Cancer Active Surveillance Study Group 2019 national investigator meeting.

David P Goldstein1, Sangeet Ghai2, Martin Corsten3, Eric Bissada4, Nathalie Audet5, Han Zhang6, Anthony Nichols7, Deric Morrison8, Stephanie Johnson-Obeski9, Donald W Anderson10, Eitan Prisman10, Nancy N Baxter11, Jennifer Jones12, Amiram Gafni13, Ian Witterick14, Anna M Sawka15.   

Abstract

Active surveillance (AS) in the management of small, low risk papillary thyroid cancer (PTC) as an alternative option to thyroidectomy, is an area of active research. A national Canadian study is proposed to evaluate the long-term outcomes of patients with small, low risk PTC who choose AS or surgery. This letter describes the proceedings of a national investigator meeting to plan the study.

Entities:  

Keywords:  Active surveillance; Conference proceeding; Thyroid cancer; Thyroidectomy

Mesh:

Year:  2021        PMID: 34172096      PMCID: PMC8228934          DOI: 10.1186/s40463-021-00514-0

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


Currently about 8600 Canadians are diagnosed with thyroid cancer per year, and this number has been rising [1]. Papillary thyroid cancer, especially low risk papillary thyroid cancer (PTC), accounts for the majority of cases [2]. Although the traditional standard management of small, low risk PTC has been thyroidectomy, there is current interest in an alternative option of active surveillance (AS). AS is close clinical and diagnostic test follow-up, with the understanding that if the disease progresses, curative intent surgery would be performed. Furthermore, patients choosing to undergo AS may change their mind and have surgery at any point in follow-up, even if the disease does not progress. Cho et al. recently reported that in a recent systematic review and meta-analysis examining AS outcomes, that within a 5-year time frame, 94.7% of untreated patients did not experience significant tumor growth and 98.4% did not experience nodal metastases [3]. Furthermore, on reviewing the relevant literature and contacting experts, we found no reports of any thyroid-cancer related deaths nor distant metastases in patients with small, low risk PTC under AS [4]. Much of the existing long-term outcome literature on thyroid cancer AS describes the clinical course of patients with papillary microcarcinoma (PTC ≤1 cm) followed in Japan [5]. A prospective study offering low risk PTC patients the choice of AS or thyroid surgery (standard of care) has been conducted at University Health Network in Toronto, Canada since May of 2016, with ongoing recruitment and follow-up [6]. Eligible patients are individuals with with small (< 2 cm maximal diameter), PTCs where the disease is confined to the thyroid (i.e. no known nodal or distant metastases nor extrathyroidal extension) and the tumor is not encroaching critical structures (trachea or course of recurrent laryngeal nerve) [6]. We herein describe the proceedings of a national investigator meeting held in Toronto on November 30, 2019, to plan a pan-Canadian prospective cohort study examining outcomes of patients with small, low risk PTC who choose AS or surgery. Ethics approval was not required as this is a summary of a meeting. The pan-Canadian study would build on the findings of the original Toronto study and ultimately the results would be reported together. The 1-day meeting was sponsored by the Canadian Institutes of Health Research (Planning Grant) and the Princess Margaret Cancer Centre Endocrine Oncology Site Group. Participants included eight head and neck surgeons, two endocrinologists, one radiologist and one statistician. There were also two patient participants invited to speak (one of whom had prior thyroidectomy for PTC and another who was under AS). The format of the scientific program was that of formal lectures with subsequent discussion. The patient participants were interviewed by a meeting host in presence of the investigators and following the interviews, the investigators had the opportunity to ask the patients’ questions. The patient participants discussed their thyroid cancer care experiences and shared insights on what they felt was important for doctors/investigators to know in caring for thyroid cancer patients. The Toronto co-primary investigators (Anna Sawka and David Goldstein) hosted/organized the meeting, moderated the discussions, and took written meeting notes. The topics discussed, all relating to low risk PTC, included: a) Review of the current experience in AS of low risk PTC – worldwide and in Canada (Toronto), b) Diagnostic imaging considerations in AS, c) Presentation and feedback on a proposed national study protocol with discussion of feasibility considerations, d) Statistical design/sample size considerations, e) Patient perspectives (interview of 2 individuals), and f) Ideas for possible future ancillary studies. The key concepts distilled from the meeting by the co-primary investigators are shown in Table 1. In concluding the meeting, the group strongly agreed that a multi-center prospective observational cohort study comparing AS and surgery for small, low risk PTC is feasible to perform in Canada. Furthermore, the participants agreed to work together in conducting such a study, across multiple Canadian institutions (operating funds for the initiation of this pan-Canadian study secured from the Canadian Institutes of Health Research and the Canadian Cancer Society).
Table 1

Key concepts at from a Canadian national investigator meeting regarding research on AS for low risk PTC

1. Currently in Canada, patients with small, low risk PTC, are typically referred for consultation on thyroid surgery (total or hemithyroidectomy) and this is established standard of care in our country.
2. Active surveillance (AS) of low risk papillary microcarcinoma (PTC ≤1 cm in maximal diameter) appears safe, based on the published literature (most of which is from Japan). More prospective long-term outcome research is needed regarding AS of larger low risk PTCs (i.e. primary tumors > 1 cm but < 2 cm).
3. Preliminary experience from Toronto, suggests that some Canadians with small, low risk PTC prefer the option of AS, over thyroid surgery, if given the choice. Patient participants at the meeting strongly valued patients being fully informed about both options, and the opportunity for patient involvement in medical decision-making.
4. Prospective AS research in low risk PTC should include patient-centered outcomes such as: disease progression requiring surgery (for patients under AS), disease persistence or recurrence requiring treatment (for the surgical arm), and validated measures of health-related quality of life and relevant related symptoms (such as anxiety).
5. Standardization of neck ultrasound interpretation and reporting, particularly with respect to eligibility criteria and criteria for disease progression, is of critical importance in conducting AS research for PTC.
6. A multi-center prospective observational cohort study comparing AS and surgery for small, low risk PTC is feasible to perform in Canada given the frequency of diagnosis, the availability of necessary technology and expertise, and a strong interest among clinicians to mitigating treatment-related harm in patients who may not benefit from surgery.
7. It will be important to compare the healthcare resource implications over time, of AS compared to surgery for low risk PTC, using Canadian healthcare costs.
Key concepts at from a Canadian national investigator meeting regarding research on AS for low risk PTC
  6 in total

1.  Active Surveillance for Small Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Se Jin Cho; Chong Hyun Suh; Jung Hwan Baek; Sae Rom Chung; Young Jun Choi; Ki-Wook Chung; Young Kee Shong; Jeong Hyun Lee
Journal:  Thyroid       Date:  2019-09-27       Impact factor: 6.568

2.  Active surveillance of low-risk papillary thyroid cancer: A meta-analysis-Methodologic critiques and tips for addressing them.

Authors:  Anna M Sawka; Lehana Thabane
Journal:  Surgery       Date:  2020-04-09       Impact factor: 3.982

3.  Projected estimates of cancer in Canada in 2020.

Authors:  Darren R Brenner; Hannah K Weir; Alain A Demers; Larry F Ellison; Cheryl Louzado; Amanda Shaw; Donna Turner; Ryan R Woods; Leah M Smith
Journal:  CMAJ       Date:  2020-03-02       Impact factor: 8.262

4.  Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease.

Authors:  William D T Kent; Stephen F Hall; Phillip A Isotalo; Robyn L Houlden; Ralph L George; Patti A Groome
Journal:  CMAJ       Date:  2007-11-20       Impact factor: 8.262

5.  A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer.

Authors:  Anna M Sawka; Sangeet Ghai; Tom Yoannidis; Lorne Rotstein; Patrick J Gullane; Ralph W Gilbert; Jesse D Pasternak; Dale H Brown; Antoine Eskander; John R de Almeida; Jonathan C Irish; Kevin Higgins; Danny J Enepekides; Eric Monteiro; Avik Banerjee; Manish Shah; Everton Gooden; Afshan Zahedi; Mark Korman; Shereen Ezzat; Jennifer M Jones; Valeria E Rac; George Tomlinson; Aleksandra Stanimirovic; Amiram Gafni; Nancy N Baxter; David P Goldstein
Journal:  Thyroid       Date:  2020-04-08       Impact factor: 6.568

6.  Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid.

Authors:  Akira Miyauchi
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.